Fibrotic and Interstitial Lung Disease
Research activity includes idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and systemic sclerosis with lung involvement, alongside bronchiectasis. The portfolio also extends to long-term management of fibrotic lung conditions and related respiratory impairment.
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Systemic sclerosis
- Bronchiectasis
Key interest is centered on respiratory function, disease progression, and chronic pulmonary symptom burden.
Inflammatory and Immune-Mediated Skin Disease
The sponsor funds studies in hidradenitis suppurativa, plaque psoriasis, and Netherton syndrome, reflecting a strong dermatology focus across inflammatory and rare genodermatoses.
- Hidradenitis suppurativa
- Plaque psoriasis
- Netherton syndrome
These areas highlight interest in chronic skin inflammation, barrier dysfunction, and symptom control in complex cutaneous disorders.
Metabolic and Cardiovascular Disease
Clinical research spans obesity, type 2 diabetes mellitus, acute myocardial infarction, and cardiovascular risk reduction, including outcomes linked to major adverse cardiovascular events.
- Obesity
- Type 2 diabetes mellitus
- Acute myocardial infarction
- Cardiovascular safety
Therapeutic interest also includes weight management in people with and without diabetes, and post-infarction cardiovascular recovery.
Hepatic and Portal Hypertension Disorders
Studies address portal hypertension, clinically significant portal hypertension, and liver disease associated with cirrhosis, including decompensated and compensated forms related to viral hepatitis and non-alcoholic steatohepatitis.
- Portal hypertension
- Clinically significant portal hypertension
- Cirrhosis
- Non-alcoholic steatohepatitis
Research interest is directed toward liver hemodynamics, complications of advanced liver disease, and portal pressure-related outcomes.
Oncology and Rare Malignancies
The oncology portfolio includes biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, lung adenocarcinoma, urothelial bladder cancer, extensive-stage small cell lung carcinoma, and glioma expressing DLL3.
- Biliary tract adenocarcinoma
- Pancreatic ductal adenocarcinoma
- Lung adenocarcinoma
- Urothelial bladder cancer
This area reflects sustained interest in difficult-to-treat solid tumours and molecularly defined cancer subtypes.
